US · Healthcare · Medical Devices
EPS came in at -0.09 against a street estimate of -0.21 — a beat of 57.1%.
Analysts rate Novocure Ltd a buy (4 buy, 3 hold, 0 sell out of 7) with an average price target of $26.86.
MIXED NovoCure delivered record revenue, stronger margins and positive adjusted EBITDA, but Optune Pax momentum slowed amid U.S. launch disruption from daraxonrasib. Q3 FY26 Japan is emerging as a major growth market, while U.S. Optune Pax access was constrained by practice disruption around daraxonrasib. Analysts focused on Optune Pax’s slowdown, EBITDA durability, 2027 growth, Japan reimbursement and R&D spending. Management emphasized temporary practice disruption, cost discipline and Japan as key growth drivers. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 14.92% |
| BlackRock Inc | 11.52% |
| Soleus Capital Management, L.P. | 8.51% |
| Vanguard Portfolio Management, LLC | 5.39% |
| Vanguard Capital Management, LLC | 4.21% |
| Morgan Stanley - Brokerage Accounts | 3.88% |
| State Street Corp | 2.46% |
| Geode Capital Management, LLC | 2.40% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Q3 2026 revenue was $193,399,000, up from $167,204,000 in Q3 2025. • Q3 2026 gross profit was $148,870,000, compared with $122,47 | 2026-10-29 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 net revenue was $193.4 million, up 16% year over year, driven primarily by 19% growth in global active patients. • Net lo | 2026-10-29 |
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • NovoCure filed a Form 8-K on October 1, 2026, regarding a September 15, 2026 press release. • Japan’s Ministry of Health, Labour | 2026-10-01 |
| Board / officer change · Q3 2026 NOVOCURE LIMITED (NVCR) - FORM 8-K SUMMARY OTHER NOTABLE POINTS • Board Change: Director Timothy Scannell retired from the Board effective September | 2026-09-09 |
| Company announcement · Q3 2026 NOVOCURE LIMITED - FORM 8-K SUMMARY HEADLINE NUMBERS • Unauthorized access to company information systems detected in mid-August 2026 • Internal pat | 2026-09-01 |
| Quarterly report · Q2 2026 NOVOCURE LIMITED - Q2 2026 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Net revenues Q2 2026: $183.6 million (up 15.6% vs Q2 2025: $158.8 mi | 2026-07-23 |
| Results announced · Q3 2026 NOVOCURE Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Net Revenues: $183.6 million, up 16% year-over-year • Global Active Patients: | 2026-07-23 |
| Reg FD disclosure · Q2 2026 NOVECORE LIMITED (NVCR) - FORM 8-K SUMMARY HEADLINE NUMBERS • Regulatory approval announced: Optune Pax® received CE (Conformité Européenne) Mark on | 2026-06-30 |
Readable in the app.
| Announcement | Date |
|---|---|
| Japan MHLW approves Optune Pax for pancreatic cancer treatment NovoCure Limited announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for treating unresectable locally advanced pancreatic cancer when used alongside ge | 2026-10-01 |
| FDA approves Optune Pax for locally advanced pancreatic cancer treatment NovoCure Limited announced that the FDA approved Optune Pax® for treating locally advanced pancreatic cancer in adult patients when used alongside gemcitabine and nab-paclitaxel chemotherapy | 2026-02-11 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Novocure Ltd — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.